Cargando…
Occurrence of comorbid diseases in patients after COVID-19
The COVID-19 pandemic has highlighted the potential impact of this disease on cardiovascular morbidity and mortality. Patients with established cardiovascular (CV) disease are at increased risk of severe infection and hospital-acquired adverse outcomes. This study aimed to investigate the prevalence...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165508/ https://www.ncbi.nlm.nih.gov/pubmed/37168295 http://dx.doi.org/10.25122/jml-2022-0168 |
_version_ | 1785038278640009216 |
---|---|
author | Kamilova, Umida Ermekbaeva, Akbal Nuritdinov, Nuriddin Khamraev, Abror Zakirova, Gulnoza |
author_facet | Kamilova, Umida Ermekbaeva, Akbal Nuritdinov, Nuriddin Khamraev, Abror Zakirova, Gulnoza |
author_sort | Kamilova, Umida |
collection | PubMed |
description | The COVID-19 pandemic has highlighted the potential impact of this disease on cardiovascular morbidity and mortality. Patients with established cardiovascular (CV) disease are at increased risk of severe infection and hospital-acquired adverse outcomes. This study aimed to investigate the prevalence and characteristics of comorbidities in COVID-19 patients. We analyzed data from 220 patients who previously contracted COVID-19. Statistical analysis was performed using SPSS software. The average age of the patients was 54.6 ± 11.4 years, and arterial hypertension (AH) was the most common comorbidity, affecting 55% of patients. Obesity was observed in one-third of patients, while coronary heart disease (CHD) and coronary heart failure (CHF) were reported in 17.7% and 11.8% of patients, respectively. Chronic kidney disease (CKD), atrial fibrillation (AF), and obstructive pulmonary disease (COPD) were less common. Cardiovascular diseases, particularly AH, were the most frequent comorbidities in COVID-19 patients. Understanding the prevalence and characteristics of comorbidities in COVID-19 patients is crucial for developing appropriate management strategies and improving clinical outcomes. Our findings highlight the importance of identifying and managing comorbidities in COVID-19 patients to reduce the risk of severe COVID-19 and improve clinical outcomes. |
format | Online Article Text |
id | pubmed-10165508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-101655082023-05-09 Occurrence of comorbid diseases in patients after COVID-19 Kamilova, Umida Ermekbaeva, Akbal Nuritdinov, Nuriddin Khamraev, Abror Zakirova, Gulnoza J Med Life Original Article The COVID-19 pandemic has highlighted the potential impact of this disease on cardiovascular morbidity and mortality. Patients with established cardiovascular (CV) disease are at increased risk of severe infection and hospital-acquired adverse outcomes. This study aimed to investigate the prevalence and characteristics of comorbidities in COVID-19 patients. We analyzed data from 220 patients who previously contracted COVID-19. Statistical analysis was performed using SPSS software. The average age of the patients was 54.6 ± 11.4 years, and arterial hypertension (AH) was the most common comorbidity, affecting 55% of patients. Obesity was observed in one-third of patients, while coronary heart disease (CHD) and coronary heart failure (CHF) were reported in 17.7% and 11.8% of patients, respectively. Chronic kidney disease (CKD), atrial fibrillation (AF), and obstructive pulmonary disease (COPD) were less common. Cardiovascular diseases, particularly AH, were the most frequent comorbidities in COVID-19 patients. Understanding the prevalence and characteristics of comorbidities in COVID-19 patients is crucial for developing appropriate management strategies and improving clinical outcomes. Our findings highlight the importance of identifying and managing comorbidities in COVID-19 patients to reduce the risk of severe COVID-19 and improve clinical outcomes. Carol Davila University Press 2023-03 /pmc/articles/PMC10165508/ /pubmed/37168295 http://dx.doi.org/10.25122/jml-2022-0168 Text en ©2023 JOURNAL of MEDICINE and LIFE https://creativecommons.org/licenses/by/3.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Original Article Kamilova, Umida Ermekbaeva, Akbal Nuritdinov, Nuriddin Khamraev, Abror Zakirova, Gulnoza Occurrence of comorbid diseases in patients after COVID-19 |
title | Occurrence of comorbid diseases in patients after COVID-19 |
title_full | Occurrence of comorbid diseases in patients after COVID-19 |
title_fullStr | Occurrence of comorbid diseases in patients after COVID-19 |
title_full_unstemmed | Occurrence of comorbid diseases in patients after COVID-19 |
title_short | Occurrence of comorbid diseases in patients after COVID-19 |
title_sort | occurrence of comorbid diseases in patients after covid-19 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165508/ https://www.ncbi.nlm.nih.gov/pubmed/37168295 http://dx.doi.org/10.25122/jml-2022-0168 |
work_keys_str_mv | AT kamilovaumida occurrenceofcomorbiddiseasesinpatientsaftercovid19 AT ermekbaevaakbal occurrenceofcomorbiddiseasesinpatientsaftercovid19 AT nuritdinovnuriddin occurrenceofcomorbiddiseasesinpatientsaftercovid19 AT khamraevabror occurrenceofcomorbiddiseasesinpatientsaftercovid19 AT zakirovagulnoza occurrenceofcomorbiddiseasesinpatientsaftercovid19 |